KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Gains from Sales and Divestitures (2016 - 2017)

Neogenomics (NEO) has disclosed Gains from Sales and Divestitures for 6 consecutive years, with $182744.0 as the latest value for Q4 2017.

  • For the quarter ending Q4 2017, Gains from Sales and Divestitures rose 452.38% year-over-year to $182744.0, compared with a TTM value of $182744.0 through Dec 2017, up 452.38%, and an annual FY2017 reading of $182744.0, up 452.38% over the prior year.
  • Gains from Sales and Divestitures was $182744.0 for Q4 2017 at Neogenomics, up from $33083.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $182744.0 in Q4 2017 and bottomed at $12820.0 in Q4 2015.
  • Average Gains from Sales and Divestitures over 5 years is $55754.4, with a median of $32000.0 recorded in 2013.
  • The sharpest move saw Gains from Sales and Divestitures tumbled 43.36% in 2014, then soared 452.38% in 2017.
  • Year by year, Gains from Sales and Divestitures stood at $32000.0 in 2013, then crashed by 43.36% to $18125.0 in 2014, then dropped by 29.27% to $12820.0 in 2015, then soared by 158.06% to $33083.0 in 2016, then skyrocketed by 452.38% to $182744.0 in 2017.
  • Business Quant data shows Gains from Sales and Divestitures for NEO at $182744.0 in Q4 2017, $33083.0 in Q4 2016, and $12820.0 in Q4 2015.